依折麦布联合他汀降脂的安全性的Meta分析

发布时间：2019-06-04 22:37

【摘要】：目的本Meta分析的目的是评估依折麦布联合他汀治疗高胆固醇血症(HC)的安全性。方法通过检索Pubmed、Cochrane Library、EMBASE三个数据库中从2002年1月至2015年10月收录的文献,两名研究者独立筛选关于依折麦布联合他汀治疗HC的随机对照试验(RCT)、提取数据、评估文献质量,采用固定效应模型计算比值比(OR),并用Review Manager 5.2统计软件进行Meta分析并得出研究结论。结果共纳入20篇RCT,包括14856个患者,依折麦布联合他汀与单用他汀治疗高胆固醇血症相比:总的不良事件发生率无差别(OR=0.95;95%CI[0.85-1.0];P=0.34),治疗退出发生率无差别(OR=1.15;95%CI[0.92-1.44];P=0.22),严重的不良事件发生率无差别(OR=1.04;95%CI[0.75-1.45];P=0.81),胃肠道不良事件发生率无差别(OR=1.26;95%CI[0.97-1.63];P=0.08),过敏事件发生率无差别(OR=0.74;95%CI[0.41-1.35];P=0.33),肌酸激酶(CK)升高10倍以上的发生率无差别(OR=1.07;95%CI[0.51-2.23];P=0.86),谷丙转氨酶(ALT)升高3倍以上的发生率无差别(OR=1.01;95%CI[0.58-1.77];P=0.96),谷草转氨酶(AST)升高3倍以上的发生率无差别(OR=1.21;95%CI[0.61-2.39];P=0.16),两组不良事件发生率相似,无统计学差异。结论这篇Meta分析表明依折麦布与他汀联用和单用他汀相比,不良事件发生率相似,两组间无统计学差异。
[Abstract]:Objective the purpose of this Meta analysis was to evaluate the safety of etomab combined with statin in the treatment of hypercholesterolemia (HC). Methods by searching the literature collected from January 2002 to October 2015 in three Pubmed,Cochrane Library,EMBASE databases, the two researchers independently screened the (RCT), extraction data of the randomized controlled trial on the treatment of HC with efolib combined with statin. The literature quality was evaluated, the ratio (OR), was calculated by fixed effect model, and the Meta analysis was carried out with Review Manager 5.2 statistical software, and the research conclusions were drawn. Results A total of 20 articles of RCT, included 14856 patients. Compared with statins alone, there was no difference in the incidence of total adverse events (OR=0.95;95%CI [0.85 鈮，

本文编号：2493049